Threshold Pharmaceuticals, Inc. Presents Encouraging Interim Results From a Phase 1 Clinical Trial of TH-302 for Solid Tumors At American Association for Cancer Research Conference On Translational Medicine

REDWOOD CITY, Calif., July 22, 2008 (PRIME NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine: Cancer Clinical Trials and Personalized Medicine, being held July 20-23, 2008, at the Hyatt Regency Hotel in Monterey, CA. Translational research with the incorporation of laboratory scientific breakthroughs into the medical treatment of cancer is a priority of the AACR which views this conference, and others like it, as a forum for current advances in translational cancer medicine and progress against cancer.

MORE ON THIS TOPIC